Pfizer's Talzenna To Compete With AZ's Lynparza In Breast Cancer After EU Okay

 
• By Kevin Grogan

European approval for its PARP inhibitor to treat BRCA-mutated breast cancer is clearly good news for the US giant but Talzenna will likely remain in Lynparza’s shadow in the near term.

Stags
Pfizer to lock horns with AZ in BRCA-mutated breast cancer market • Source: Shutterstock

More from Anticancer

More from Therapy Areas